Abstract
The prevalence of prostate cancer has shown a marked increase in China. Most patients are presented with metastasis at diagnosis.It has been proven by clinical trials that besides androgen deprivation therapy, Abiraterone and docetaxel can improve the overall survival of metastatic hormone sensitive prostate cancer patients with high risks.For metastatic castration-resistant prostate cancer treatment, docetaxel, abiraterone and enzalutamide, etc., have demonstrated significant overall survival benefit. Among them, docetaxel and abiraterone have accumulated adequate experience in Chinese patients. Therefore, it is quite important for Chinese physicians to make reasonable clinical decisions based on these treatment regimes. In order to improve patients' survival and life quality, Chinese Anticancer Association Genitourinary Oncology Committee composed this expert consensus to help physicians to make reasonable decisions.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
